Cannapharmarx, Inc. (CPMD): Gross Profit
-$2.08M
Year ended 2025-12-31
-$1.51M
Trailing 12 months to 2026-06-30
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$2.08M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$2.93M | n/a | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $0 | n/a | 2025-04-10, From 2023-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$2.08M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $940.0K | n/a |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $619.0K | -15.6% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $803.0K | -57.4% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $248.7K | -32.3% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $452.9K | +32.0% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $734.4K | n/a |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $223.8K | +0.4% |
| Bio Essence Corp (BIOE) | 2025-12-31 | $1.43M | +558.0% |
Compare CPMD, NRXP, IGC, LGVN side by side · Screen every company in Pharmaceutical Preparations ↗